<p>Biotricity（BTCY）已举行其第二季度财报电话会议。请继续阅读会议的主要亮点。</p>
<h3>认识您的 ETF AI 分析师</h3>
<ul>
<li>了解 TipRanks 的_ETF_ AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 所揭示的见解。</li>
</ul>
<p>Biotricity 最近的财报电话会议传达了强烈的积极情绪，突显了显著的收入增长、改善的毛利润和正向的 EBITDA。尽管出现了净亏损和运营费用增加，但战略进展和积极的财务趋势表明公司前景乐观。</p>
<h2>收入增长</h2>
<p>在 2026 财年的第二季度，Biotricity 报告的收入较去年同期增长了 19%，达到 390 万美元。这一增长凸显了公司成功的市场策略和服务的日益普及。</p>
<h2>毛利润改善</h2>
<p>该季度公司的毛利润总计 320 万美元，比去年同期增长了 29.4%。毛利润率提高了 660 个基点，达 81.9%，反映了公司的运营效率和成本管理。</p>
<h2>正向 EBITDA</h2>
<p>Biotricity 连续第二个季度实现了 373,000 美元的正向 EBITDA，标志着朝着全面盈利的进展。这一成就突显了公司有效的财务管理和运营策略。</p>
<h2>心脏监测技术的进展</h2>
<p>Biocore Pro 2 心脏监测仪的开发以及 Biocore Pro 销售的扩展，包括与医院网络和诊所的试点项目，展示了 Biotricity 在医疗保健领域对创新和技术进步的承诺。</p>
<h2>战略合作伙伴关系和市场扩展</h2>
<p>Biotricity 扩大了在退伍军人事务部和领先家庭护理集团的覆盖范围，并在肺部和神经学领域建立了合作伙伴关系。这些战略举措预计将增强公司的市场存在感和增长潜力。</p>
<h2>归属于普通股东的净亏损</h2>
<p>该财年的三个月净亏损为 772,000 美元，较去年同期的 160 万美元有所改善。这一净亏损的减少表明公司财务健康状况的改善。</p>
<h2>运营费用增加</h2>
<p>第二季度的运营费用较去年同期增加了 5.1%，达到 290 万美元。尽管费用增加，公司仍继续专注于成本管理和运营效率。</p>
<h2>前瞻性指导</h2>
<p>Biotricity 的前瞻性指导强调持续增长和盈利能力。公司旨在利用规模经济，并将利润投资于扩大市场份额和商业团队。通过专注于创新、战略合作伙伴关系和商业扩展，Biotricity 有望实现持续增长。</p>
<p>总之，Biotricity 的财报电话会议反映了强烈的积极情绪，得益于显著的收入增长、改善的毛利润和正向的 EBITDA。公司的战略进展和对创新的关注使其在未来成功的道路上处于良好位置，尽管面临净亏损和运营费用增加等挑战。</p>

BTCY

<p>Biotricity 第二季度的财报电话会议强调了显著的收入增长，增长率为 19%，达到 390 万美元，毛利润提高了 29.4%，达到 320 万美元，且 EBITDA 为 37.3 万美元，呈现正值。尽管净亏损为 77.2 万美元，且运营费用增加，但在心脏监测技术和市场扩展方面的战略进展表明了良好的前景。公司旨在通过创新和战略合作伙伴关系实现持续增长和盈利</p>

<p>Biotricity ((BTCY)) has held its Q2 earnings call. Read on for the main highlights of the call.</p>
<div class="lb-trans"><p>Biotricity（BTCY）已举行其第二季度财报电话会议。请继续阅读会议的主要亮点。</p>
</div><h3>Meet Your ETF AI Analyst</h3>
<div class="lb-trans"><h3>认识您的 ETF AI 分析师</h3>
</div><ul>
<li>Discover how TipRanks' <em>ETF</em> AI Analyst can help you make smarter investment decisions</li>
<li>Explore ETFs TipRanks' users love and see what insights the <strong><em>ETF</em> AI Analyst</strong> reveals about the ones you follow.</li>
</ul>
<div class="lb-trans"><ul>
<li>了解 TipRanks 的_ETF_ AI 分析师如何帮助您做出更明智的投资决策</li>
<li>探索 TipRanks 用户喜爱的 ETF，并查看 <strong><em>ETF</em> AI 分析师</strong> 对您关注的 ETF 所揭示的见解。</li>
</ul>
</div><p>Biotricity’s recent earnings call conveyed a strong positive sentiment, highlighting significant revenue growth, improved gross profit, and positive EBITDA. Despite a net loss and increased operating expenses, the strategic advancements and positive financial trends suggest a promising outlook for the company.</p>
<div class="lb-trans"><p>Biotricity 最近的财报电话会议传达了强烈的积极情绪，突显了显著的收入增长、改善的毛利润和正向的 EBITDA。尽管出现了净亏损和运营费用增加，但战略进展和积极的财务趋势表明公司前景乐观。</p>
</div><h2>Revenue Growth</h2>
<div class="lb-trans"><h2>收入增长</h2>
</div><p>For the second quarter of fiscal ’26, Biotricity reported a 19% increase in revenue compared to the corresponding period in the previous year, reaching $3.9 million. This growth underscores the company’s successful market strategies and increasing adoption of its services.</p>
<div class="lb-trans"><p>在 2026 财年的第二季度，Biotricity 报告的收入较去年同期增长了 19%，达到 390 万美元。这一增长凸显了公司成功的市场策略和服务的日益普及。</p>
</div><h2>Improved Gross Profit</h2>
<div class="lb-trans"><h2>毛利润改善</h2>
</div><p>The company’s gross profit for the quarter totaled $3.2 million, marking a 29.4% increase from the prior year period. The gross profit percentage improved by 660 basis points to 81.9%, reflecting the company’s operational efficiencies and cost management.</p>
<div class="lb-trans"><p>该季度公司的毛利润总计 320 万美元，比去年同期增长了 29.4%。毛利润率提高了 660 个基点，达 81.9%，反映了公司的运营效率和成本管理。</p>
</div><h2>Positive EBITDA</h2>
<div class="lb-trans"><h2>正向 EBITDA</h2>
</div><p>Biotricity achieved a positive EBITDA of $373,000 for the second consecutive quarter, signaling progress towards full profitability. This achievement highlights the company’s effective financial management and operational strategies.</p>
<div class="lb-trans"><p>Biotricity 连续第二个季度实现了 373,000 美元的正向 EBITDA，标志着朝着全面盈利的进展。这一成就突显了公司有效的财务管理和运营策略。</p>
</div><h2>Advancements in Cardiac Monitoring Technology</h2>
<div class="lb-trans"><h2>心脏监测技术的进展</h2>
</div><p>The development of the Biocore Pro 2 cardiac monitor and the expansion of Biocore Pro sales, including pilot programs with hospital networks and clinics, demonstrate Biotricity’s commitment to innovation and technology advancement in healthcare.</p>
<div class="lb-trans"><p>Biocore Pro 2 心脏监测仪的开发以及 Biocore Pro 销售的扩展，包括与医院网络和诊所的试点项目，展示了 Biotricity 在医疗保健领域对创新和技术进步的承诺。</p>
</div><h2>Strategic Partnerships and Market Expansion</h2>
<div class="lb-trans"><h2>战略合作伙伴关系和市场扩展</h2>
</div><p>Biotricity expanded its reach into VA and leading home care groups, as well as forming partnerships in pulmonary and neurology sectors. These strategic moves are expected to enhance the company’s market presence and growth potential.</p>
<div class="lb-trans"><p>Biotricity 扩大了在退伍军人事务部和领先家庭护理集团的覆盖范围，并在肺部和神经学领域建立了合作伙伴关系。这些战略举措预计将增强公司的市场存在感和增长潜力。</p>
</div><h2>Net Loss Attributable to Common Shareholders</h2>
<div class="lb-trans"><h2>归属于普通股东的净亏损</h2>
</div><p>The net loss for the fiscal 3-month period was $772,000, an improvement from $1.6 million in the prior year period. This reduction in net loss indicates progress in the company’s financial health.</p>
<div class="lb-trans"><p>该财年的三个月净亏损为 772,000 美元，较去年同期的 160 万美元有所改善。这一净亏损的减少表明公司财务健康状况的改善。</p>
</div><h2>Increase in Operating Expenses</h2>
<div class="lb-trans"><h2>运营费用增加</h2>
</div><p>Operating expenses for the second quarter increased by 5.1% to $2.9 million compared to the same period last year. Despite this increase, the company continues to focus on cost management and operational efficiency.</p>
<div class="lb-trans"><p>第二季度的运营费用较去年同期增加了 5.1%，达到 290 万美元。尽管费用增加，公司仍继续专注于成本管理和运营效率。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>Biotricity’s forward-looking guidance emphasizes continued growth and profitability. The company aims to leverage its economies of scale and invest profits into expanding its market share and commercial team. With a focus on innovation, strategic partnerships, and commercial expansion, Biotricity is poised for sustained growth.</p>
<div class="lb-trans"><p>Biotricity 的前瞻性指导强调持续增长和盈利能力。公司旨在利用规模经济，并将利润投资于扩大市场份额和商业团队。通过专注于创新、战略合作伙伴关系和商业扩展，Biotricity 有望实现持续增长。</p>
</div><p>In summary, Biotricity’s earnings call reflects a strong positive sentiment, driven by significant revenue growth, improved gross profit, and positive EBITDA. The company’s strategic advancements and focus on innovation position it well for future success, despite challenges such as net loss and increased operating expenses.</p>
<div class="lb-trans"><p>总之，Biotricity 的财报电话会议反映了强烈的积极情绪，得益于显著的收入增长、改善的毛利润和正向的 EBITDA。公司的战略进展和对创新的关注使其在未来成功的道路上处于良好位置，尽管面临净亏损和运营费用增加等挑战。</p>
</div>

Biotricity 的财报电话会议：增长与乐观前景